<DOC>
	<DOCNO>NCT01632904</DOCNO>
	<brief_summary>The purpose RELIEF study compare symptom polycythemia vera ( PV ) subject treated ruxolitinib versus subject treat hydroxyurea ( HU ) measure percent subject achieve clinically meaningful symptom improvement ( ie , total symptom score reduction â‰¥ 50 % reduction ) Week 16 compare Baseline . The study also design demonstrate response durable continued treatment .</brief_summary>
	<brief_title>Randomized Switch Study From Hydroxyurea Ruxolitinib RELIEF Polycythemia Vera Symptoms : The Relief Study</brief_title>
	<detailed_description>This Phase 3 multicenter , double-blind , double-dummy , randomize study . Only subject PV receive HU least 12 week , receive stable dose screening , still symptom related PV enrol . Subjects randomize ( 1:1 ) 1 2 treatment arm : A : ruxolitinib HU-placebo B : HU ruxolitinib-placebo Subjects randomize either arm may eligible transition open-label ruxolitinib Week 16 .</detailed_description>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Subjects must currently report symptom stable dose HU monotherapy eligible continue HU study randomization . Before screen , subject must receive HU least 12 week AND receive stable dose . Subjects must meet baseline symptom criterion Subjects meet least 1 follow criterion : No 2 phlebotomy within 6 month screen OR No palpable splenomegaly . Subjects must hematocrit control within 35 % 48 % ( inclusive ) randomization . Subjects inadequate liver renal function screening . Subjects clinically significant infection require therapy Subjects know active hepatitis A , B , C screen know HIV positivity . Subjects active malignancy previous 2 year Subjects clinically significant cardiac disease ( Class III IV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Polycythemia Vera</keyword>
	<keyword>PV</keyword>
</DOC>